Literature DB >> 1725022

The effect of ramipril on ambulatory blood pressure: a multicenter trial.

J F Burris1.   

Abstract

The antihypertensive efficacy of ramipril was evaluated using 24-h noninvasive ambulatory sphygmomanometry in this double-blind, placebo-controlled study. One hundred subjects with mild-to-moderate essential hypertension were randomized to ramipril, 10 mg or placebo once daily for a 4-week treatment period. Ramipril decreased systolic and diastolic blood pressures throughout the 24-h period after dosing. Blood pressures measured manually 24 h postdose also showed that ramipril significantly reduced supine and standing blood pressures when compared with placebo. Incidences of adverse events were similar in the two study groups. Ramipril proved to be a well-tolerated agent with a sustained 24-h antihypertensive effect in this study.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1725022

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

1.  Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril.

Authors:  J M van Griensven; R C Schoemaker; A F Cohen; H G Luus; M Seibert-Grafe; H J Röthig
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 2.  Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.

Authors:  Balraj S Heran; Michelle My Wong; Inderjit K Heran; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.